We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Batm Advanced Communications Ld | BVC | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.40 | 2.13% | 19.20 | 16:35:29 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 19.20 | 18.80 |
| Industry Sector |
|---|
| TECHNOLOGY HARDWARE & EQUIPMENT |
| Top Posts |
|---|
Posted at 25/4/2024 14:53 by bigjon1 It is clear that the middle east tensions is leading to a discounted share price but this won't be the case forever and at some point share price will catch up with the fundamental value, especially as more investors see the growth from core businesses over the coming months/years. BATM just need to continue building - the increase in share price will follow. |
Posted at 22/4/2024 15:22 by resistance1 From the Anglonordic Life Sciences Conference last week at which a range of exciting breakthroughs were pitched to invited sector investors, institutions and backers, ADOR presented their NatLab. Key summary & highlights below for those looking for further insight into this point of exciting new care diagnostic system:Natlab is based on the Isothermal Amplification method, which is new (but scientifically proven) and is recognised as significantly superior to PCR testing. It is widely tipped to replace PCR. ADOR is the only company to employ this new method and get it to work with a patented system. 1 trial has been successfully completed, and another 2 trials (Italy & Greece) will complete in Q4 ’24. 3 trials are required for full validation, and with 1 already successful it is looking good. The worldwide diagnostic market is worth $32bn for the diseases so far covered. More panels are being added to increase market scope. The system has many patents worldwide including China/Japan/USA/Euro The system is commercially ready and production ready after trial completion. The system allows immediate testing to results for many disease groups in 45 mins. With traditional systems you have to do multiple repeat tests for every disease variant taking time and costing far more. The system can be used by nursing staff/junior lab technicians at the point of care and is foolproof to operate. Speed of diagnosis means lives saved and care time reduced The system allows for huge cost savings, speed and staff cost savings. Staff cost savings probably being the most important by far. |
Posted at 17/4/2024 19:28 by resistance1 After all that I enquired about attending. The answer came back they were oversubscribed. Seems to be a very good forum to showcase ADOR Natlab to leading investors in the sector — that’s what this conference is fundamentally all about. |
Posted at 15/4/2024 13:46 by resistance1 The (eventual) sale of non core businesses will go someway to unbundle and refocus the business from an investors viewpoint. As you say commercial traction on Edgility vital. From the perspective of ADOR successful trials should lead to an IP sale. Nat Lab seems to offer genuine operational cost advantages in terms of cost per diagnosis and also speed of processing time compared with competitors. |
Posted at 09/4/2024 09:39 by gbenson1 The shorts have sucked the life out of this stock, investors are keeping their powder dry and the share price just keeps moving south, I hate shorting it moved investing from interesting to just becoming a gamble at the casino, they should ban it.. |
Posted at 14/3/2024 07:25 by paulisi They stated that the valuation was unchanged, but one of the investors didn't participate in the latest fundraising and thus the structure of ownership changed |
Posted at 12/3/2024 20:55 by bigjon1 Despite challenges, such as inflation impacting costs, year end results provide a positive outlook in my eyes. While results are steady, it is clear investors expect more. I am expecting the strategic shifts towards sales and marketing to drive revenue growth, with potential for acquisitions and sales in key areas like cybersecurity. |
Posted at 12/3/2024 17:28 by car1pet The technology group is focusing on its core cyber security, network solutions and diagnostics activities, but investors should wait before getting excited againMarch 12, 2024 by Simon Thompson Full-year cash profit up 12 per cent to $9.3mn Adjusted pre-tax profit up from $2.8mn to $4.8mn Potential for M&A activity and divestments Technology group BATM Advanced Communications (BVC:19.25p) is undergoing a corporate reorganisation, restructuring non-core activities and prioritising its core cyber security, network solutions and diagnostics activities. As part of the new strategy, the directors have engaged investment banks in both Israel and the US to explore corporate activity to add to the group’s capabilities, and to secure attractive terms for disposals. BATM closed the 2023 financial year with net cash of $31.7mn after deducting $4.5mn of lease liabilities and $4.6mn of bank debt, so has ample firepower available for acquisitions. It is also scaling up sales and marketing functions. In the short term, the increased investment will impact profit, hence why analysts at house broker Shore Capital reined in their 2024 cash profit estimate from $13.5mn to $9.4mn. This implies a flat performance year on year. However, analyst Robin Speakman notes that there is scope for “better forecast outcomes and so upgrades are also real and high from this point”. |
Posted at 12/3/2024 16:46 by resistance1 I see Simon Thompson has done a piece today in the Investors ChronicleHe rates it a Hold and like all of us here wants to see tangible results on the restructuring before getting excited. In the article there's some fresh insight on the divisional operations which he must have unearthed himself. |
Posted at 29/2/2024 07:23 by kooba BANG ON echoBATM Advanced Communications Limited ("BATM" or the "Group") Notice of Results BATM (LSE: BVC; TASE: BVC), a leading provider of real-time technologies for networking solutions and medical laboratory systems, gives notice that it will be announcing its preliminary results for the year ended 31 December 2023 on Tuesday 12 March 2024. Investor & Analyst Presentation Moti Nagar, CEO, and Ran Noy, CFO, will be holding a webinar for analysts and investors on Wednesday 13 March 2024 at 4.30pm GMT. To register to participate or submit a question in advance, please use the following link: hxxps://forms.gle/4i |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
